Anzeige
Meldung des Tages: Alle investieren in DEN neuen Boommarkt 2026! JETZT diese Aktie entdecken

Quest Diagnostics News

Aktie
WKN:  904533 ISIN:  US74834L1008 US-Symbol:  DGX Land:  USA
179,32 €
-0,04 €
-0,02%
22:43:53 Uhr
Depot/Watchlist
Marktkapitalisierung *
16,68 Mrd. €
Streubesitz
0,32%
KGV
19,57
Dividende
2,82 EUR
Dividendenrendite
1,91%
Nachhaltigkeits-Score
35 %
Index-Zuordnung
S&P 500

Quest Diagnostics News

02.03.26 - PR Newswire
Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results
Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results PR Newswire
26.02.26 - PR Newswire
Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer PR Newswire
25.02.26 - PR Newswire
Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference
Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference PR Newswire
10.02.26 - PR Newswire
Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share PR ...
10.02.26 - PR Newswire
Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization
Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase ...
02.02.26 - PR Newswire
Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease PR Newswire
21.01.26 - PR Newswire
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year PR Newswire
15.01.26 - PR Newswire
Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect
Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect PR Newswire
08.01.26 - PR Newswire
Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026
Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 PR Newswire
06.01.26 - PR Newswire
Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium
Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium PR Newswire
05.01.26 - PR Newswire
Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan
Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan PR Newswire
19.12.25 - PR Newswire
Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
11.11.25 - PR Newswire
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics Declares Quarterly Cash Dividend PR Newswire
03.11.25 - PR Newswire
Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference
Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference PR Newswire
27.10.25 - PR Newswire
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis PR Newswire
24.10.25 - PR Newswire
MVZ HPH führt ctDNA-Bluttest zur Krebsüberwachung in Europa ein, basierend auf der Haystack MRD®-Technologie von Quest Diagnostics®
MVZ HPH führt ctDNA-​Bluttest zur Krebsüberwachung in Europa ein, basierend auf der Haystack MRD®-Technologie von Quest Diagnostics® PR Newswire
21.10.25 - PR Newswire
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 PR Newswire
17.10.25 - PR Newswire
MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®
MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics® PR Newswire
25.09.25 - PR Newswire
Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025
Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025 PR Newswire
23.09.25 - PR Newswire
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-​First Epic Collaboration PR Newswire

Newssuche

Videos

newspaper
09:00 Uhr +1,65%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »